NEUTRALIZING ANTIBODY MARKET ANALYSIS

The global neutralizing antibody market size was valued at US$ 190.44 billion in 2023 and is projected to reach US$ 338.86 billion by 2030 at a compound annual growth rate (CAGR) of 8.6% from 2023 to 2030. The rising prevalence of infectious diseases, increasing research and development activities, and growing demand for personalized medicine are the key factors driving the growth of the market.

• Increasing prevalence of infectious diseases: The rising prevalence of infectious diseases such as HIV, hepatitis B, hepatitis C, and malaria is driving the growth of the neutralizing antibody market. Neutralizing antibodies are used to treat these diseases by binding to the surface of the virus or bacteria and preventing it from infecting the cells.
• Increasing research and development activities: The rising investments in research and development are another key factor driving the growth of the market. Pharmaceutical companies are investing heavily in the development of new neutralizing antibodies for the treatment of various diseases.
• Growing demand for personalized medicine: The growing demand for personalized medicine is also driving the growth of the market. Personalized medicine is a type of medicine that is tailored to the individual needs of the patient. Neutralizing antibodies can be used to treat diseases in a personalized manner.

Analyst’s View:

The neutralizing antibody market refers to the pharmaceutical sector dedicated to the research, development, production, and distribution of monoclonal antibodies designed to neutralize specific pathogens, particularly viruses. These antibodies are crucial in combating infectious diseases, and they have gained significant prominence during the COVID-19 pandemic, with monoclonal antibody therapies being used for both treatment and prevention. The market's growth is driven by the need to address emerging viral variants and other infectious diseases. Advancements in manufacturing processes, distribution networks, and potential collaborations further contribute to the expansion of this market. It plays a vital role in the global healthcare landscape, offering solutions for the prevention and treatment of various infectious diseases.

Neutralizing Antibody Market Regional Insights

• North America: North America is the largest market for neutralizing antibodies, accounting for a market share of 41.8% in 2023. The region is home to some of the leading pharmaceutical companies, such as Genentech, BioLegend, and Thermo Fisher Scientific. These companies are investing heavily in the development of new neutralizing antibodies for the treatment of various diseases.
• Europe: Europe is the second largest market for neutralizing antibodies, accounting for a market share of 28.2% in 2023. The region has a strong presence of pharmaceutical companies such as Roche, Novartis, and Sanofi. These companies are also investing heavily in the development of new neutralizing antibodies.
• Asia Pacific: Asia Pacific is the fastest growing market for neutralizing antibodies, accounting for a market share of 22.0% in 2021. The region is home to a large and growing population, which is susceptible to a variety of infectious diseases. The rising prevalence of infectious diseases, coupled with the increasing investments in research and development, is driving the growth of the market in Asia Pacific.

Figure 1. Global Neutralizing Antibody Market Share (%), by Region, 2023

To learn more about this report, Request sample copy

Neutralizing Antibody Market Drivers

• COVID-19 Pandemic: The COVID-19 pandemic has been a major driver for the neutralizing antibody market. Neutralizing antibodies have played a critical role in the treatment and prevention of COVID-19, with several monoclonal antibody therapies receiving emergency use authorizations or approvals. The demand for neutralizing antibodies against SARS-CoV-2 has surged, leading to significant market growth. For instance, on November 2021, Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases provided a data according to which the investigational monoclonal antibody ADG20 is being assessed for its ability to effectively combat the Omicron SARS-CoV-2 variant, along with other notable variants of concern. ADG20 has been specifically developed to offer comprehensive and robust neutralization of SARS-CoV-2, including its concerning variants, in the context of preventing and treating COVID-19. It holds the promise of providing protection for up to one year with just a single injection.
• Increasing Prevalence of Infectious Diseases: The global prevalence of infectious diseases, such as HIV/AIDS, hepatitis, and respiratory infections, remains high. Neutralizing antibodies are a promising therapeutic option for the treatment of these diseases. As the prevalence of such infectious diseases continues to rise, the demand for neutralizing antibodies is expected to increase. For instance, on May 2022, World Health Organization's (WHO) published annual estimates which shows that , there are globally 300–500 million cases of malaria, 333 million cases of sexually transmitted diseases (syphilis, gonorrhea, chlamydia, and trichomonas), 33 million cases of HIV/AIDS, 14 million people infected with tuberculosis.
• Rising Incidence of Autoimmune Disorders: Autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, and lupus, are on the rise globally. Neutralizing antibodies have shown effectiveness in targeting and neutralizing specific molecules involved in autoimmune responses. The growing incidence of autoimmune disorders is expected to drive the demand for neutralizing antibodies for therapeutic purposes.
• Advancements in Biotechnology and Monoclonal Antibody Development: The field of biotechnology has witnessed significant advancements in recent years, leading to improved techniques for monoclonal antibody development. This has facilitated the production of high-quality neutralizing antibodies with enhanced efficacy and specificity. Advancements in biotechnology are expected to drive the development of novel neutralizing antibodies and expand the market. For instance, on January 2022, GSK, one of the global pharmaceutical company and Vir Biotechnology, a commercial-stage immunology company announced that they have signed an agreement with US Government to purchase an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19.

Neutralizing Antibody Market Opportunities

• Emerging Infectious Diseases: The emergence of new infectious diseases, such as novel viral strains or zoonotic infections, presents opportunities for the development and utilization of neutralizing antibodies. As new pathogens emerge, there is a need for effective therapeutic interventions, and neutralizing antibodies can play a crucial role in treating and preventing these diseases.
• Expansion into Oncology: Neutralizing antibodies have shown promise in the field of oncology, particularly in targeted cancer therapies. There is a growing understanding of specific tumor antigens that can be targeted by neutralizing antibodies to inhibit tumor growth and enhance the body's immune response against cancer cells. Expanding the application of neutralizing antibodies into the field of oncology presents significant opportunities for market growth.
• Combination Therapies: Combining neutralizing antibodies with other treatment modalities, such as chemotherapy, radiation therapy, or immune checkpoint inhibitors, can lead to synergistic effects and improved patient outcomes. The development of combination therapies involving neutralizing antibodies opens up new opportunities to enhance treatment efficacy across various disease indications.
• Therapeutic Areas Beyond Infectious Diseases: While neutralizing antibodies have been predominantly used in infectious diseases, there is potential for their application in other therapeutic areas. For example, neutralizing antibodies targeting specific molecules involved in autoimmune diseases, neurodegenerative disorders, and cardiovascular conditions could offer novel treatment options. Exploring the therapeutic potential of neutralizing antibodies in these areas represents an opportunity for market expansion.

Neutralizing Antibody Market Trends

• Increasing Focus on COVID-19 Treatment and Prevention: The COVID-19 pandemic continues to drive significant demand for neutralizing antibodies. Monoclonal antibody therapies, such as Regeneron, one of the leading biotechnology company’s casirivimab/imdevimab and Eli Lilly and Company, one of the global leading b pharmaceutical company’s bamlanivimab/etesevimab, have received emergency use authorizations or approvals for the treatment and prevention of COVID-19. The ongoing research and development of neutralizing antibodies targeting SARS-CoV-2 variants reflect the industry's focus on combating the pandemic.
• Development of Multi-Specific and Bispecific Antibodies: Multi-specific and bispecific antibodies are gaining attention in the neutralizing antibody market. These antibodies are designed to simultaneously target multiple antigens or receptors, offering enhanced therapeutic effects and increased specificity. The demand for enhanced treatment results and the ability to tackle intricate diseases is propelling the advancement of multi-specific and bispecific neutralizing antibodies.
• Advancements in Antibody Engineering and Design: Antibody engineering and design techniques continue to advance, enabling the generation of optimized neutralizing antibodies. Methods such as antibody humanization, affinity maturation, and Fc (antibodies) engineering are used to enhance antibody efficacy, half-life, and safety profiles. The incorporation of novel platforms, including antibody fragments and antibody-drug conjugates, further expands the possibilities for therapeutic development.
• Shift Towards Subcutaneous Administration: Traditionally, neutralizing antibodies have been administered intravenously, requiring hospital or clinic visits. However, there is a growing trend towards subcutaneous administration, enabling self-administration or administration in outpatient settings. This shift improves patient convenience, reduces healthcare burden, and increases accessibility to neutralizing antibody therapies.

Neutralizing Antibody Market Restraints

• High Cost of Development and Treatment: Developing and manufacturing neutralizing antibodies is a complex and costly process. The extensive research and development efforts, clinical trials, and manufacturing expenses contribute to high development costs. Additionally, the high price of neutralizing antibody treatments can limit accessibility, particularly in healthcare systems with limited resources and budget constraints.
• Regulatory Challenges: Regulatory challenges can pose significant restraints on the neutralizing antibody market. Obtaining regulatory approvals for new antibody therapies involves rigorous safety and efficacy evaluations. Regulatory agencies often require extensive clinical data, which can lead to longer development timelines and increased costs. Navigating the regulatory landscape can be challenging for companies, especially for novel or complex neutralizing antibodies.

Recent Developments

New product launches

• Evusheld (tixagevimab and cilgavimab) by AstraZeneca, one of the global pharmaceutical company: This antibody cocktail was approved by the U.S.FDA in December 2021 for the prevention of COVID-19 in adults who are at high risk of severe disease.
• Sotrovimab by Vir Biotechnology: This antibody was approved by the U.S.FDA in October 2021 for the treatment of mild to moderate COVID-19 in adults who are at high risk of progression to severe disease.
• REGEN-COV2 (casirivimab and imdevimab) by Regeneron Pharmaceuticals and Rocheone of the leading healthcare company: This antibody cocktail was approved by the U.S.FDA in November 2020 for the treatment of mild to moderate COVID-19 in adults who are at high risk of progression to severe disease.

Acquisition and partnerships

• In September 2021, Sanofi, one of the leading pharmaceutical company acquired Translate Bio for US$3.20 billion. Translate Bio is a gene therapy company that develops treatments for rare diseases using neutralizing antibodies.
• In September 2020, Gilead Sciences, a research-based biopharmaceutical company acquired Immunomedics for US$21.00 billion. Immunomedics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs).
• In October 2020, IAVI, a nonprofit scientific research organization, Serum Institute of India Pvt. Ltd., a leading manufacturer of vaccines and biologics and Merck KGaA, a leading science and technology company, announced their partnership and agreement to develop SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) co-invented by IAVI and Scripps Research as innovative interventions to address the COVID-19 pandemic.

Figure 2. Global Neutralizing Antibody Market Share (%), by application, 2023

To learn more about this report, Request sample copy

Top companies in Neutralizing Antibody Market

• Regeneron Pharmaceuticals, Inc.
• Eli Lilly and Company
• AstraZeneca PLC
• GlaxoSmithKline plc
• Sanofi SA
• Roche Holding AG
• Novartis AG
• Merck & Co., Inc.
• Pfizer Inc.
• Johnson & Johnson
• Moderna, Inc.
• CSL Limited
• Sinovac Biotech Ltd.

*Definition: The neutralizing antibody market refers to the global market for antibodies that have the ability to neutralize or inhibit the activity of specific pathogens, such as viruses or bacteria. These antibodies can be naturally produced by the immune system or developed through biotechnology. They are used in various applications, including the treatment and prevention of infectious diseases, as well as in research and diagnostic settings. The market involves the production, development, and commercialization of neutralizing antibodies by pharmaceutical companies, biotechnology firms, and research institutions.